Actively Recruiting

Phase Not Applicable
Age: 50Years - 80Years
All Genders
ID06040905

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

Led by Chung Shan Medical University · Updated on 2024-02-07

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

C

Chung Shan Medical University

Lead Sponsor

N

National Science and Technology Council

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying the effects of coenzyme Q10 supplementation on people with mild cognitive impairment (MCI) and Alzheimer's disease (AD) who also have high blood sugar (hyperglycemia) and either no muscle loss or early muscle loss (pre-sarcopenia). This study aims to understand how coenzyme Q10 affects blood sugar, brain health markers like brain-derived neurotrophic factor (BDNF), muscle-related proteins, and cognitive function. Alzheimer's disease is linked to brain changes similar to diabetes, and coenzyme Q10 is an antioxidant that may influence energy production and blood sugar regulation. The study is designed as a randomized, double-blind, placebo-controlled trial where participants receive either 300 mg of coenzyme Q10 daily (150 mg twice a day) or a placebo for 12 weeks. After the initial period, participants will switch treatments to compare effects. Researchers collect data on mental function, nutrition, muscle strength, quality of life, and mood. Blood samples are taken before and after treatment to measure coenzyme Q10 levels, BDNF, oxidative stress, antioxidant capacity, and other muscle and metabolic markers. Participants will be evaluated using cognitive tests, muscle strength measurements, physical performance assessments, dietary records, and questionnaires on quality of life and depression. The primary outcomes include fasting glucose, HbA1C, insulin, C-peptide, BDNF, and muscle-related proteins after 12 weeks. Secondary outcomes include oxidative stress markers, antioxidant capacity, cognitive scores, muscle mass, grip strength, and physical performance. The study will last through the treatment and follow-up periods to monitor changes and understand how coenzyme Q10 may affect metabolism and cognition in this group.

CONDITIONS

Brief Title

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

Who Can Participate

Age: 50Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of mild cognitive impairment (MCI)
  • Clinical diagnosis of Alzheimer's Disease
  • MCI and AD patients with hyperglycemia (fasting glucose >=100 mg/dL)
  • MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance)
  • Must be able to swallow tablets
Not Eligible

You will not qualify if you...

  • Cancer patients
  • Severe heart, lung, liver, and kidney diseases
  • Severe disability or aphasia
  • Malnutrition (body weight changes > 5% within one month)
  • Using coenzyme Q10 supplements
  • Warfarin therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit

Treatment

Duration - 12 weeks per treatment period

Participants receive coenzyme Q10 supplementation or placebo to study its effects on glucose metabolism, muscle function, and cognitive status.

Visits occur at baseline and after 12 weeks for each treatment period

Trial Site Locations

Total: 1 location

1

Chung Shan Medical University Hospital

Taichung, Taiwan

Actively Recruiting

Loading map...

Research Team

P

Ping-Ting Lin, Ph.D.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Similar Trials

Comparison of Cardiac [18F]-MFBG PET Versus [123I]-MIBG SPEC...

Parkinson Disease

Actively Recruiting

2 locations

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 ...

Alzheimer Disease

Actively Recruiting

25 locations

A Phase Ia Clinical Trial to Assess Safety, Tolerability, an...

Hyperglycemia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here